M55 Stock Overview
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.82 |
| 52 Week High | US$19.80 |
| 52 Week Low | US$4.06 |
| Beta | 2.11 |
| 1 Month Change | 4.37% |
| 3 Month Change | 51.22% |
| 1 Year Change | 139.03% |
| 3 Year Change | -46.52% |
| 5 Year Change | 0.91% |
| Change since IPO | -19.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| M55 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.3% | -4.9% | -1.5% |
| 1Y | 139.0% | -19.9% | 0.9% |
Return vs Industry: M55 exceeded the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: M55 exceeded the German Market which returned 0.9% over the past year.
Price Volatility
| M55 volatility | |
|---|---|
| M55 Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: M55's share price has been volatile over the past 3 months.
Volatility Over Time: M55's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 339 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics, Inc. Fundamentals Summary
| M55 fundamental statistics | |
|---|---|
| Market cap | €943.72m |
| Earnings (TTM) | -€8.50m |
| Revenue (TTM) | €55.15m |
16.6x
P/S Ratio-107.8x
P/E RatioIs M55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M55 income statement (TTM) | |
|---|---|
| Revenue | US$58.75m |
| Cost of Revenue | US$174.81m |
| Gross Profit | -US$116.06m |
| Other Expenses | -US$107.00m |
| Earnings | -US$9.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | -197.55% |
| Net Profit Margin | -15.42% |
| Debt/Equity Ratio | 0% |
How did M55 perform over the long term?
See historical performance and comparison